title: [Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders].
abstract: The clinical efficacy and the safety of concomitant therapy with fluconazole and recombinant human granulocyte colony stimulating factor (rhG-CSF) was compared with fluconazole monotherapy in neutropenic patients with hematological disorders. The clinical efficacy rate was 73.5% (25/34) in the combination therapy and 48.1% (37/77) in monotherapy. The difference between the two is statistically significant. Side effects were not observed in the combination group, but laboratory abnormalities were found in 6 patients with an incident rate of 11%. The combination therapy with fluconazole and rhG-CSF may be selected as empiric therapy for systemic fungal infection associated with hematological disorders, since this combination therapy showed high efficacy and low incident of side effects. Some patients, however, did not show increased neutrophil counts in spite of rhG-CSF administration.
authors.affiliation: Department of Clinical Laboratory, Faculty of Medicine, University of Tokyo.
authors.forename: K
authors.initials: K
authors.lastname: Kitamura
authors.forename: K
authors.initials: K
authors.lastname: Miyagawa
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Obayashi
authors.forename: I
authors.initials: I
authors.lastname: Aoki
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: A
authors.initials: A
authors.lastname: Togawa
authors.forename: E
authors.initials: E
authors.lastname: Shindou
authors.forename: Y
authors.initials: Y
authors.lastname: Wakabayashi
authors.forename: T
authors.initials: T
authors.lastname: Ohshima
authors.forename: A
authors.initials: A
authors.lastname: Horikoshi
authors.forename: T
authors.initials: T
authors.lastname: Nomura
authors.forename: I
authors.initials: I
authors.lastname: Ohki
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Kamakura
authors.forename: A
authors.initials: A
authors.lastname: Oguchi
authors.forename: K
authors.initials: K
authors.lastname: Toyama
authors.forename: M
authors.initials: M
authors.lastname: Yaguchi
authors.forename: N
authors.initials: N
authors.lastname: Aoki
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: S
authors.initials: S
authors.lastname: Irie
authors.forename: S
authors.initials: S
authors.lastname: Fujioka
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D000069585:Filgrastim; D015725:Fluconazole / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D009503:Neutropenia / Q000150:complications; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D011994:Recombinant Proteins
chemical_list: D000935:Antifungal Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015725:Fluconazole; D000069585:Filgrastim